Literature DB >> 320230

Twice weekly prophylactic therapy in haemophilia A.

A Aronstam, P J Kirk, J McHardy, J W Culver-James, D S McLellan, P Turk, S G Rainsford, M Slattery.   

Abstract

Factor VIII-containing materials were administered to four severely affected haemophiliacs twice weekly in doses calculated to raise the factor VIII level to either 15% or 30% of average normal. The pooled results from those patients with statistically similar baseline bleeding frequencies showed a significant reduction in bleeding frequency on both doses in the first 48 hours. The 30% dose produced a more significant reduction than the 15% dose in the first 24 hours, but there was no significant difference between the two doses in the second 24 hours. It appears that to reduce the bleeding frequency of severely affected haemophiliacs by 60% would require a two-and-a-half-fold increase in therapeutic materials. A 90% reduction would need nine times the amount of material currently in use.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 320230      PMCID: PMC476643          DOI: 10.1136/jcp.30.1.65

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  5 in total

1.  Prophylaxis in haemophilia: a double-blind controlled trial.

Authors:  A Aronstam; P G Arblaster; S G Rainsford; P Turk; M Slattery; M R Alderson; D E Hall; P J Kirk
Journal:  Br J Haematol       Date:  1976-05       Impact factor: 6.998

2.  A three-year study of adolescent boys suffering from haemophilia and allied disorders.

Authors:  S G Rainsford; A Hall
Journal:  Br J Haematol       Date:  1973-05       Impact factor: 6.998

3.  Our experience in Sweden with prophylaxis on haemophilia.

Authors:  I M Nilsson; M Blombäck; A Ahlberg
Journal:  Bibl Haematol       Date:  1970

4.  Prophylactic therapy in classical hemophilia: a preliminary report.

Authors:  P M Robinson; P Tittley; R K Smiley
Journal:  Can Med Assoc J       Date:  1967-09-09       Impact factor: 8.262

5.  A trial of prophylactic replacement therapy in haemophilia and Christmas disease.

Authors:  D M Ramsay; A C Parker
Journal:  J Clin Pathol       Date:  1973-04       Impact factor: 3.411

  5 in total
  7 in total

Review 1.  Hemophilia treatment in historical perspective: a review of medical and social developments.

Authors:  F R Rosendaal; C Smit; E Briët
Journal:  Ann Hematol       Date:  1991-02       Impact factor: 3.673

Review 2.  [The role of self-infusion treatment for the patient with haemophilia (author's transl)].

Authors:  K Schimpf
Journal:  Blut       Date:  1978-02

Review 3.  Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.

Authors:  Omotola O Olasupo; Megan S Lowe; Ashma Krishan; Peter Collins; Alfonso Iorio; Davide Matino
Journal:  Cochrane Database Syst Rev       Date:  2021-08-18

Review 4.  Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.

Authors:  Hans-Christoph Rossbach
Journal:  Vasc Health Risk Manag       Date:  2010-03-03

Review 5.  Primary prophylaxis in children with haemophilia.

Authors:  Antonio Coppola; Mirko Di Capua; Ciro De Simone
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443

6.  Transfusion requirements of adolescents with severe haemophilia A.

Authors:  A Aronstam; D S McLellan; P Turk
Journal:  J Clin Pathol       Date:  1979-09       Impact factor: 3.411

Review 7.  Achieving the unimaginable: Health equity in haemophilia.

Authors:  Mark W Skinner; Diane Nugent; Pam Wilton; Brian O'Mahony; Gerry Dolan; Jamie O'Hara; Erik Berntorp
Journal:  Haemophilia       Date:  2019-11-13       Impact factor: 4.287

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.